Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Hobart, Jeremy; Ziemssen, Tjalf; Feys, Peter; Linnebank, Michael; Goodman, Andrew; Farrell, Rachel; Hupperts, Raymond; R. Blight, Andrew; Englishby, Veronica; McNeill, Manjit; Chang, Ih; Paiva da Silva Lima, Gabriel; Elkins, Jacob; behalf of the ENHANCE study investigators, On

doi:10.1007/s40263-018-0586-5

Public

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Published in CNS Drugs • Dec 10, 2018

Authors:

Jeremy Hobart

Tjalf Ziemssen

Peter Feys

Abstract

Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impair...

Subject

Expanded Disability Status Scale

Physical therapy

Multiple sclerosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!